Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation

Internal Medicine

Volumn 54, Issue 10, 2015, Pages 1167-1173

  Nagao, Tomoyuki ^a   Inden, Yasuya ^a   Shimano, Masayuki ^a   Fujita, Masaya ^a   Yanagisawa, Satoshi ^a   Kato, Hiroyuki ^a   Ishikawa, Shinji ^a   Miyoshi, Aya ^a   Okumura, Satoshi ^a   Ohguchi, Shiou ^a   Yamamoto, Toshihiko ^a   Yoshida, Naoki ^a,b   Hirai, Makoto ^c   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; Catheter ablation; Dabigatran

Indexed keywords

AMIODARONE; DABIGATRAN; ISOPRENALINE; PROTAMINE; VERAPAMIL; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

ABLATION THERAPY; ADULT; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GROIN HEMATOMA; HEART ATRIUM PACING; HEART FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD RENAL IMPAIRMENT; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RETROSPECTIVE STUDY; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; HEMORRHAGE; PROCEDURES; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; WARFARIN;

EID: 84929313799     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.54.3520     Document Type: Article

References (34)

1. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339: 659-666, 1998
2. Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation 105: 1077-1081, 2002
3. Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3: 32-38, 2010
4. Wazni OM, Beheiry S, Fahmy T, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: Comparison of strategies of anticoagulation management in the periprocedural period. Circulation 116: 2531-2534, 2007
5. Hussein AA, Martin DO, Saliba W, et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: A safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 6: 1425-1429, 2009
6. Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio. Circulation 121: 2550-2556, 2010
7. Lee DS, Dorian P, Downar E, et al. Thrombogenicity of radiofrequency ablation procedures: What factors influence thrombin generation? Europace 3: 195-200, 2001
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151, 2009
9. Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 10: 483-489, 2013
10. Kaseno K, Naito S, Nakamura K, et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 76: 2337-2342, 2012
11. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 59: 1168-1174, 2012
12. Steinberg BA, Hasselblad V, Atwater BD, et al. Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: A meta-analysis of observational studies. J Interv Card Electrophysiol 37: 213-221, 2013
13. Sardar P, Nairooz R, Chatterjee S, Wetterslev J, Ghosh J, Aronow WS. Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. Am J Cardiol 113: 1173-1177, 2014
14. Providencia R, Albenque JP, Combes S, et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: A systematic review and meta-analysis. Heart 100: 324-335, 2014
15. Shurrab M, Morillo CA, Schulman S, et al. Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: A meta-analysis. Can J Cardiol 29: 1203-1210, 2013
16. Bin Abdulhak AA, Khan AR, Tleyjeh IM, et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: A systematic review and meta-analysis. Europace 15: 1412-1420, 2013
17. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (re-ly) trial. Circulation 123: 2363-2372, 2011
18. Hankey GJ, Eikelboom JW. Dabigatran etexilate: A new oral thrombin inhibitor. Circulation 123: 1436-1450, 2011
19. Ouyang F, Bansch D, Ernst S, et al. Complete isolation of left atrium surrounding the pulmonary veins: New insights from the double-lasso technique in paroxysmal atrial fibrillation. Circulation 110: 2090-2096, 2004
20. Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation: Mapping of the electrophysiologic substrate. J Am Coll Cardiol 43: 2044-2053, 2004
21. Oral H, Chugh A, Good E, et al. Radiofrequency catheter ablation of chronic atrial fibrillation guided by complex electrograms. Circulation 115: 2606-2612, 2007
22. Haissaguerre M, Sanders P, Hocini M, et al. Catheter ablation of long-lasting persistent atrial fibrillation: Critical structures for termination. J Cardiovasc Electrophysiol 16: 1125-1137, 2005
23. Tada H, Oral H, Sticherling C, et al. Double potentials along the ablation line as a guide to radiofrequency ablation of typical atrial flutter. J Am Coll Cardiol 38: 750-755, 2001
24. Maddox W, Kay GN, Yamada T, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol 24: 861-865, 2013
25. Pernod G, Albaladejo P, Godier A, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis 106: 382-393, 2013
26. Ellis CR, Kaiser DW. The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients. Vasc Health Risk Manag 9: 341-352, 2013
27. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor vii for acute intracerebral hemorrhage. N Engl J Med 358: 2127-2137, 2008
28. Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor viia in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2: 263-267, 2005
29. Konduru SV, Cheema AA, Jones P, Li Y, Ramza B, Wimmer AP. Differences in intraprocedural acts with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin. J Interv Card Electrophysiol 35: 277-284; discussion 284, 2012
30. Winkle RA, Mead RH, Engel G, Patrawala RA. Safety of lower activated clotting times during atrial fibrillation ablation using open irrigated tip catheters and a single transseptal puncture. Am J Cardiol 107: 704-708, 2011
31. Di Biase L, Gaita F, Toso E, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm 11: 791-798, 2014
32. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64: 292-303, 2007
33. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103: 1116-1127, 2010
34. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15 (Suppl 1): 9S-16S, 2009.